BioNTech Founders Depart, Senator Probes FDA Rare Disease
BioNTech co-founders plan to leave by 2026 to launch a new mRNA venture, while a U.S. senator investigates FDA's rare disease drug approval denials.
By James Liu
FDA
3 articles tagged "FDA"
FDA Reduces Advisory Meetings Amid Controversial Decisions
The FDA is cutting back on public advisory committee meetings as contested drug approval decisions mount, raising transparency concerns for patients nationwide.
By Priya Patel
FDA Advisory Committees Decline & Biosimilar Rule Changes
FDA faces scrutiny over a 63% drop in advisory committee meetings in 2025 and new moves to ease biosimilar development requirements in 2026.